SWEDEN, STOCKHOLM – 2 May, 2012. Pergamum AB today announced that Dr. Margit Mahlapuu was appointed as the company’s Chief Scientific Officer (CSO). Pergamum AB was formed in 2009 with the objective of synergetically aggregating a number of programs in…
MoreNews
Pergamum Completes Patient Recruitment to the Phase II Clinical Trial for Prevention of Post-Surgical Adhesions
SWEDEN, STOCKHOLM – February 10, 2012. Pergamum AB announced today that the last patient has been dosed in a randomized Phase II trial of PXL01 for prevention of postsurgical adhesions. Karolinska Development AB is the majority owner of Pergamum. In…
MorePergamum Initiates Phase II Trial With DPK-060 in Outer Ear Infections
STOCKHOLM, SWEDEN – January 16, 2012. Pergamum AB today announced that the first patient has been dosed in a randomized Phase II study of DPK‐060 for the treatment of patients with external otitis (swimmers ear). “Every year more than 10…
MorePergamum Featured in a Swedish Magazine on Leading Edge Technology for Combating Antibiotics Resistance (Swedish)
Små, positivt laddade molekyler som dödar bakterier så snabbt att de inte hinner utveckla resistens. Det lilla utvecklingsbolaget Pergamum vid Karolinska Development har patent på hur tre så kallade antimikrobiella peptider ska kunna användas för att bekämpa infektioner i sår…
MoreTorbjörn Bjerke Appointed Chairman of Pergamum AB
Torbjörn Bjerke, Chief Executive Officer, Karolinska Development AB (publ), was appointed Chairman of the Board of Directors following the Annual Shareholders’ Meeting in Pergamum AB on June 22, 2011. “Several of Pergamum’s development initiatives have the potential of changing future…
MoreCompletion and Approval of the 2010 Annual Report of Pergamum AB
The annual report for 2010 was approved at the Annual Shareholders’ Meeting, which for the first time had been prepared in accordance with IFRS standards for the Pergamum group. For more information, please contact: Jonas Ekblom, CEO Phone: +46-8-470 37…
MorePergamum Relocated to New Head Offices
Stockholm, June 1, 2011. Pergamum AB has completed the relocation to its new head offices in the Stockholm area. The new premises are in walking distance from the campus of Karolinska Institutet. “We are delighted to make this office relocation,…
MoreCorrado Sablone Joins Pergamum AB as Chief Financial Officer
STOCKHOLM, May 30, 2011. Pergamum, a Swedish biotechnology company with focus on the development of new treatments for wounds and skin infections, today announced the hire of Corrado Sablone as Chief Financial Officer. Mr Sablone joins Pergamum from Coca Cola…
More